兴发娱乐

Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.

By the end of 2022, Fosun Pharma had more than 260 projects for drugs under development, including innovator drugs, biosimilars, generic drugs, and those for consistency evaluation. During the reporting period, the company applied for 249 patents in the pharmaceutical segment, including 16 US patents and 17 PCT applications, and was granted 48 patents.

According to 2022 Annual Report
*Unit: RMB billion yuan

  • 5.097 billion
    The R&D investment in the pharmaceutical business
  • 5.885 billion
    The R&D investment
  • 3,600+
    R&D staff
  • 1,900+
    employees with a master's degree or above

In China

  • 20
    Concurrent clinical trials
  • 7
    IND applications
  • 3
    NDA applications

In The United States And Australia

  • 3
    Clinical trials
  • 1
    IND application
  • 2 项
    IND approvals
High-tech: PCG - protein therapy, cell therapy, gene therapy, small molecule pioneering/best innovator drugs
  • Double-antibody
  • Stem cell therapy
  • mRNA therapy
  • Gene editing
Tumor/immunology, neurological disorders (chronic degeneration, stroke, etc.), chronic/metabolic diseases, infectious/rare diseases
  • Tumor/immunology
  • Central Nervous System
  • Metabolic/chronic diseases
  • Infectious/rare diseases